Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study

BK polyomavirus associated nephropathy (BKPyVAN) is a significant clinical issue in kidney transplant (KT) recipients. No specific therapy is currently available, although treatment with leflunomide may be part of the therapeutic strategy. Here, we sought to examine the impact of leflunomide on the evolution of BKPyVAN.

[1]  R. Porcher,et al.  Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[2]  T. Mohanakumar,et al.  Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation. , 2017, Journal of the American Society of Nephrology : JASN.

[3]  J. Chapman,et al.  Clearance of BK Virus Nephropathy by Combination Antiviral Therapy With Intravenous Immunoglobulin , 2017, Transplantation direct.

[4]  M. Halim,et al.  Long-Term Follow-Up of Active Treatment Versus Minimization of Immunosuppressive Agents in Patients With BK Virus-Associated Nephropathy After Kidney Transplant. , 2016, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[5]  N. Babel,et al.  European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  Devin Tian,et al.  The impact of surveillance and rapid reduction in immunosuppression to control BK virus‐related graft injury in kidney transplantation , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  L. Braun-Parvez,et al.  Risk Factors for BK Virus Infection in the Era of Therapeutic Drug Monitoring , 2013, Transplantation.

[8]  P. Randhawa,et al.  BK Polyomavirus in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  C. Bratton,et al.  Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[10]  G. Mourad,et al.  Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients , 2011, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  D. Muruve,et al.  Anti-BK Virus Mechanisms of Sirolimus and Leflunomide Alone and in Combination: Toward a New Therapy for BK Virus Infection , 2010, Transplantation.

[12]  M. Mihatsch,et al.  Reducing Immunosuppression Preserves Allograft Function in Presumptive and Definitive Polyomavirus‐Associated Nephropathy , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  E. Woodle,et al.  Assessment of Efficacy and Safety of FK778 in Comparison With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy , 2010, Transplantation.

[14]  Steve Doucette,et al.  Treatment of Polyomavirus Infection in Kidney Transplant Recipients: A Systematic Review , 2010, Transplantation.

[15]  K. Abbott,et al.  Retransplantation After BK Virus Nephropathy in Prior Kidney Transplant: An OPTN Database Analysis , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  H. Hirsch,et al.  Leflunomide Inhibition of BK Virus Replication in Renal Tubular Epithelial Cells , 2009, Journal of Virology.

[17]  T. Benzing,et al.  Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. , 2009, Transplantation proceedings.

[18]  J. Schold,et al.  Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[19]  I. D. de Boer,et al.  Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[20]  G. Mourad,et al.  Does Reduction in Immunosuppression in Viremic Patients Prevent BK Virus Nephropathy in De Novo Renal Transplant Recipients? A Prospective Study , 2008, Transplantation.

[21]  R. Orentas,et al.  Successful Treatment of BK Viremia Using Reduction in Immunosuppression Without Antiviral Therapy , 2008, Transplantation.

[22]  C. Mengelle,et al.  Leflunomide treatment for polyomavirus BK‐associated nephropathy after kidney transplantation , 2007, Transplant international : official journal of the European Society for Organ Transplantation.

[23]  C. Mengelle,et al.  Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome. , 2007, Transplantation proceedings.

[24]  J. Jordan,et al.  Treatment of Renal Allograft Polyoma BK Virus Infection with Leflunomide , 2006, Transplantation.

[25]  S. Hariharan,et al.  BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. , 2005, Kidney international.

[26]  W. Al-Nakib,et al.  BK virus nephropathy in renal transplant recipients in Kuwait: a preliminary report. , 2005, Transplantation proceedings.

[27]  J. Millis,et al.  Leflunomide for polyomavirus type BK nephropathy. , 2005, The New England journal of medicine.

[28]  M. Schnitzler,et al.  Incidence of BK with Tacrolimus Versus Cyclosporine and Impact of Preemptive Immunosuppression Reduction , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  P. Randhawa,et al.  Effect of Leflunomide and Cidofovir on Replication of BK Virus in an In Vitro Culture System , 2005, Transplantation.

[30]  M. Schnitzler,et al.  Prospective, Pilot, Open‐Label, Short‐Term Study of Conversion to Leflunomide Reverses Chronic Renal Allograft Dysfunction , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  T. Klimkait,et al.  Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. , 2002, The New England journal of medicine.

[32]  J. Fink,et al.  Clinical course of polyoma virus nephropathy in 67 renal transplant patients. , 2002, Journal of the American Society of Nephrology : JASN.

[33]  A. Chong,et al.  Experiences with leflunomide in solid organ transplantation. , 2002, Transplantation.

[34]  K. Khalili,et al.  Human Polyomaviruses: Molecular and Clinical Perspectives , 2002 .

[35]  J. Fink,et al.  BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. , 2002, Clinical transplants.

[36]  D. Knight,et al.  Inhibition of Cytomegalovirus in vitro and in vivo by the Experimental Immunosuppressive Agent Leflunomide , 2000, Intervirology.

[37]  F. Uckun,et al.  Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton′s Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-β-Methyl-N-(2,5-Dibromophenyl)Propenamide]* , 1999, The Journal of Biological Chemistry.

[38]  A. Chong,et al.  Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide (*) , 1995, The Journal of Biological Chemistry.

[39]  A. Chong,et al.  Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. , 1994, Transplantation.

[40]  K. Shah,et al.  High prevalence of antibodies to BK virus, an SV40-related papovavirus, in residents of Maryland. , 1973, The Journal of infectious diseases.